Autosomal recessive polycystic kidney disease (ARPKD)
On ABGC's listListed on the ABGC Self-Study GuideLog in to starLast updated Nov 3, 2026
A prenatal ultrasound at 20 weeks reveals bilaterally enlarged, echogenic kidneys and oligohydramnios. After birth, the infant has Potter sequence and congenital hepatic fibrosis.
AR; PKHD1 (fibrocystin, also called polyductin). Biallelic loss-of-function variants; two truncating variants give the most severe disease.
Fibrocystin is a large single-pass transmembrane protein expressed in the kidney, bile ducts, and pancreas, and its function is poorly understood. It localizes to primary cilia, where several cystic kidney disease proteins act, and it joins polycystin-1 and polycystin-2 in a complex in extracellular vesicles. Preclinical models suggest it regulates cAMP, protein kinase A, SRC-STAT3, and Myc signaling, which seem to jointly regulate epithelial proliferation and morphogenesis. Fibrocystin deficiency may also promote liver fibrosis by recruiting macrophages.
The mechanism is loss of function. In the liver, ductal plate remodeling fails, so embryonic bile duct structures persist; this congenital hepatic fibrosis is present at birth and leads to portal hypertension. Reduced fetal kidney function causes oligohydramnios and pulmonary hypoplasia, and enlarged kidneys limiting diaphragm movement may add to it.
Most truncating variants are expected to remove all protein function, and two of them usually mean early or perinatal death; at least one missense variant usually gives a milder course, though severe disease still occurs. Time to kidney replacement therapy through adolescence did not differ significantly by genotype group. PKHD1 has 86 exons with complex splicing, and deep intronic variants are found by genome sequencing.
- Renal: Enlarged, echogenic kidneys (collecting duct ectasia), oligohydramnios (severe)
- Hepatic: Congenital hepatic fibrosis (all patients) → portal hypertension
- Severe: neonatal death from pulmonary hypoplasia
- Milder: presents in childhood with hypertension, hepatic fibrosis
- Imaging (prenatal or postnatal ultrasound) shows bilaterally enlarged, echogenic kidneys with poor corticomedullary differentiation, often with oligohydramnios
- Congenital hepatic fibrosis with biliary ductal plate malformation supports the diagnosis
- PKHD1 molecular testing confirms the diagnosis and enables carrier and prenatal testing
- Respiratory support for neonatal pulmonary hypoplasia; antihypertensive therapy for systemic hypertension
- Renal replacement therapy (dialysis, transplant) for progressive kidney failure
- Surveillance for portal hypertension complications (varices, hypersplenism, cholangitis); combined liver-kidney transplant in selected cases
- Variable; those surviving neonatal period may have better outcomes